Glimepiride , Pioglitazone Hydrochloride & Metformine Hydrochloride (Sustained Release) Tablets | Brand – Minmek-PG1 | Manufacturer – CARDMEK | Pack of 1×10 Tab

Description:Minmek-PG1 combines Glimepiride, Pioglitazone Hydrochloride, and Metformin Hydrochloride (Sustained Release) for comprehensive management of type 2 diabetes. This combination works synergistically to improve insulin sensitivity, enhance insulin secretion, and regulate glucose production, providing effective blood sugar control throughout the day.Key Benefits:Glimepiride: Stimulates insulin secretion from the pancreasPioglitazone Hydrochloride: Improves insulin sensitivity and reduces glucose productionMetformin Hydrochloride (Sustained Release): Ensures steady control of blood glucose by decreasing liver glucose production and enhancing insulin actionProvides long-lasting glucose control with fewer fluctuationsComposition:Glimepiride: Enhances pancreatic insulin releasePioglitazone Hydrochloride: Increases insulin sensitivity in muscles and fatMetformin Hydrochloride (Sustained Release): Reduces glucose production in the liver and improves insulin effectivenessRecommended Usage:Take 1 tablet daily with food or as directed by your healthcare provider. Dosage may be adjusted based on individual blood sugar levels and response to treatment.